SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-129303
Filing Date
2021-04-23
Accepted
2021-04-23 17:23:51
Documents
5
Period of Report
2021-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A d173777ddef14a.htm DEF 14A 361538
2 GRAPHIC g173777g0418140317345.jpg GRAPHIC 38835
3 GRAPHIC g173777g0418140317798.jpg GRAPHIC 40183
4 GRAPHIC g173777g21n15.jpg GRAPHIC 22853
5 GRAPHIC g173777g71p99.jpg GRAPHIC 50472
  Complete submission text file 0001193125-21-129303.txt   569906
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39112 | Film No.: 21850751
SIC: 2836 Biological Products, (No Diagnostic Substances)